S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
Study Details
Study Description
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan, leucovorin, fluorouracil, and oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well different regimens of induction chemotherapy followed by chemoradiotherapy work in treating patients with locally advanced adenocarcinoma of the rectum.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
OBJECTIVES:
-
Determine the feasibility of obtaining a pre-treatment determination of intratumoral molecular markers (TS, DPD, and ERCC-1) for use in selection of the appropriate regimen for induction cytotoxic combination chemotherapy in patients with cT3-4 rectal adenocarcinoma.
-
Determine the response probability (unconfirmed, complete and partial) in patients treated with targeted induction cytotoxic chemotherapy.
-
Determine the toxicity of targeted induction cytotoxic chemotherapy and chemoradiotherapy in these patients.
-
Determine the response probability in these patients treated with chemoradiotherapy.
OUTLINE: This is a multicenter study.
-
Induction chemotherapy: Patients are assigned to 1 of 3 treatment groups based on molecular analysis of the pretreatment tumor specimen.
-
Group I (lower likelihood of resistance to a fluorouracil-based regimen): Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1.
-
Group II (higher likelihood of resistance to a fluorouracil-based regimen): Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on day 1.
-
Group III (high likelihood of sensitivity to oxaliplatin and fluorouracil therapy): Patients receive oxaliplatin IV over 90 minutes and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1.
Treatment in all groups repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
Patients are evaluated for response approximately 2 weeks after the completion of induction chemotherapy. Patients with stable disease or better receive chemoradiotherapy.
- Chemoradiotherapy: Beginning approximately 3 weeks after the completion of induction chemotherapy, patients receive oral capecitabine twice daily continuously for 5 weeks and concurrent radiotherapy once daily 5 days a week for 5 weeks.
After chemoradiotherapy, patients may undergo attempted surgical resection at the discretion of the treating physician.
Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 10-65 patients will be accrued for this study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Irinotecan + 5-FU + Leucovorin Irinotecan 180mg/m2, IV for 90min on Day 1, q 2 wk x 4 cycles; 5-FU 400 mg/m2, IV bolus on Day 1, q 2 wk x 4 cycles; 5-FU 2.4 g/m2 IV for 46 hours on Day 1, q 2 wk x 4 cycles; Leucovorin 200 mg/m2 IV for 2 hours on Day 1, q 2 wk x4 cycles. |
Drug: capecitabine
825mg/m2 BID, PO, daily
Drug: fluorouracil
Bolus + IV for 46 hrs on Day 1
Drug: irinotecan hydrochloride
IV infusion over 90 min on Day 1
Drug: leucovorin calcium
200mg/m2 IV 2 hour infusion on Day 1
Radiation: radiation therapy
Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
Drug: Pyridoxine
50mg TID, PO daily
|
Experimental: Irinotecan + Oxaliplatin Irinotecan 175mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; Oxaliplatin 85mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles |
Drug: capecitabine
825mg/m2 BID, PO, daily
Drug: irinotecan hydrochloride
IV infusion over 90 min on Day 1
Drug: oxaliplatin
85mg/m2 IV infusion for 90minutes on Day 1
Radiation: radiation therapy
Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
Drug: Pyridoxine
50mg TID, PO daily
|
Experimental: Oxaliplatin + 5-FU + Leucovorin Oxaliplatin 85mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; 5-FU 400mg/m2 IV bolus on Day 1, q 2wk x4 cycles; 5-FU 2.4g/m2 IV for 46 hours on Day 1, q 2wk x4 cycles; Leucovorin 200mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles. |
Drug: capecitabine
825mg/m2 BID, PO, daily
Drug: fluorouracil
Bolus + IV for 46 hrs on Day 1
Drug: leucovorin calcium
200mg/m2 IV 2 hour infusion on Day 1
Drug: oxaliplatin
85mg/m2 IV infusion for 90minutes on Day 1
Radiation: radiation therapy
Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
Drug: Pyridoxine
50mg TID, PO daily
|
Outcome Measures
Primary Outcome Measures
- Response (confirmed and unconfirmed response, complete response, partial response) []
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed primary adenocarcinoma of the rectum
-
Locally advanced disease (clinical T3-4, N0-2, M0) based on at least 1 of the following criteria:
-
Clinically fixed tumors on rectal examination with tumor adherent to the pelvic sidewall and/or sacrum
-
Sciatica attributed to sacral root invasion with CT scan/MRI evidence of the lack of clear tissue plane is considered evidence of fixation
-
Hydronephrosis on CT scan or intravenous pyelogram of ureteric or bladder invasion by cystoscopy and cytology or biopsy
-
Invasion into the prostate, vagina, or uterus
-
Transmural penetration of tumor through the muscularis propria as evidenced by CT scan or MRI and endorectal ultrasound
-
Distal border of the tumor must be at or below the peritoneal reflection (within 12 cm of the anal verge) by proctoscopic examination
-
Measurable disease by x-ray, scans, or physical examination
-
Available tumor tissue to determine molecular profile of the tumor before study treatment
-
No clinical evidence of high-grade (lumen diameter < 1 cm) large bowel obstruction unless a diverting colostomy has been performed
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Zubrod 0-2
Life expectancy
- Not specified
Hematopoietic
-
WBC ≥ 3,500/mm^3
-
Absolute neutrophil count ≥ 1,500/mm^3
-
Platelet count ≥100,000/mm^3
Hepatic
-
Bilirubin ≤ 1.5 times upper limit of normal (ULN)
-
SGOT or SGPT ≤ 2.5 times ULN
-
Alkaline phosphatase ≤ 2.5 times ULN
Renal
-
See Disease Characteristics
-
Creatinine ≤ 1.5 times ULN OR
-
Estimated creatinine clearance > 50 mL/min
Cardiovascular
-
No significant cardiac disease
-
No recent myocardial infarction
Gastrointestinal
-
See Disease Characteristics
-
Able to swallow oral medication
-
No active inflammatory bowel disease
Other
-
Not pregnant or nursing
-
Fertile patients must use effective contraception
-
No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
-
No prior unanticipated severe reaction to study drugs
-
No known dihydropyrimidine dehydrogenase deficiency
-
No serious uncontrolled infection
-
No other serious medical illness that would preclude study treatment
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy for colon or rectal cancer
Endocrine therapy
- Not specified
Radiotherapy
-
No prior pelvic radiotherapy
-
No prior intra-operative radiotherapy or brachytherapy
-
No concurrent intra-operative radiotherapy or brachytherapy
-
No concurrent intensity-modulated radiotherapy
Surgery
-
See Disease Characteristics
-
See Radiotherapy
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Southwest Oncology Group
- National Cancer Institute (NCI)
Investigators
- Study Chair: Charles R. Thomas, MD, The University of Texas Health Science Center at San Antonio
- Study Chair: Heinz-Josef Lenz, MD, University of Southern California
- Study Chair: Robert P. Whitehead, MD, University of Texas
- Study Chair: James L. Abbruzzese, MD, M.D. Anderson Cancer Center
- Study Chair: Stephen R. Smalley, MD, Radiation Oncology Center of Olathe
- Study Chair: Morton S. Kahlenberg, MD, The University of Texas Health Science Center at San Antonio
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000334469
- U10CA032102
- S0304